While tamoxifen use is associated with clear benefits in the treatment of hormone-sensitive breast cancer, it also exhibits partial oestrogen agonist activity that is associated with adverse events, ...
Following relapse on endocrine therapy for advanced, hormone receptor-positive breast cancer, it is common for patients to experience responses to alternative endocrine agents. Fulvestrant (‘Faslodex’ ...
Please provide your email address to receive an email when new articles are posted on . The combination of anastrozole and fulvestrant extended median survival of women with hormone-receptor–positive ...
Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated ...
APPROVAL EXPANDS USE AND OFFERS ADDITIONAL OPTION FOR WOMEN WITH HR+, HER2- METASTATIC BREAST CANCER (WILMINGTON, Del., March 2, 2016) – AstraZeneca today announced that the US Food and Drug ...
September 17, 2010 — The US Food and Drug Administration (FDA) has approved a 500-mg dose of fulvestrant intramuscular injection (Faslodex; AstraZeneca) for the treatment of hormone receptor–positive ...
Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer. Patients with HR-positive, HER2-negative locally advanced or ...
Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up Newswise — A study co-authored by a Loyola researcher and ...
SAN ANTONIO, Dec. 6, 2023 /PRNewswire/ -- MEDSIR today announced the results from the PARSIFAL-LONG study, a 5-year extended follow-up of the PARSIFAL study on ...
Gedatolisib plus Faslodex, with or without Ibrance, improved PFS in hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The VIKTORIA-1 trial demonstrated significant PFS ...
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s fulvestrant formulation has not met the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results